Patent 12090163 was granted and assigned to Cipla on September, 2024 by the United States Patent and Trademark Office.
The invention relates to pharmaceutical compositions comprising ((((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)oxy)methyl pivalate or a pharmaceutically acceptable derivative thereof, optionally with an additional agent, methods of making them, and their use in medicine.